Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
← catalyst calendarNCT01838512 · readout in 1,319 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,555estimated
Sites
130
Countries
Canada, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2012-06-13 | actual | When the study began enrolling |
| Primary completion | 2030-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2013-04-24 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS) for participants with relapsed/refractory multiple myeloma (RRMM)
measured Up to 5 years
Overall Survival (OS) for participants with newly-diagnosed multiple myeloma (NDMM)
measured Up to 8 years
Progression-Free Survival (PFS) for participants with RRMM
measured Up to 5 years
Progression-Free Survival (PFS) for participants with NDMM
measured Up to 8 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed